Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million.
Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release.
Xeris develops technology platforms to enable ready-to-use, room-temperature stable formulations of injectable and infusible therapies.
Get the full story at our sister site, Drug Delivery Business News.